Insider Selling: Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Sells $253,935.12 in Stock

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) insider Neal Flomenberg sold 232,968 shares of the business’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $1.09, for a total transaction of $253,935.12. Following the sale, the insider now directly owns 3,595,608 shares of the company’s stock, valued at approximately $3,919,212.72. This represents a 6.08 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Neal Flomenberg also recently made the following trade(s):

• On Monday, March 10th, Neal Flomenberg sold 70,384 shares of Tevogen Bio stock. The stock was sold at an average price of $1.09, for a total transaction of $76,718.56.
• On Thursday, March 6th, Neal Flomenberg sold 88,519 shares of Tevogen Bio stock. The stock was sold at an average price of $1.10, for a total transaction of $97,370.90.
• On Tuesday, March 4th, Neal Flomenberg sold 14,639 shares of Tevogen Bio stock. The stock was sold at an average price of $1.28, for a total transaction of $18,737.92.

Tevogen Bio Stock Performance

NASDAQ TVGN opened at $1.17 on Monday. Tevogen Bio Holdings Inc. has a 52 week low of $0.26 and a 52 week high of $6.25. The company has a 50-day moving average price of $1.36 and a two-hundred day moving average price of $1.18.

Wall Street Analyst Weigh In

Separately, D. Boral Capital restated a “buy” rating and issued a $10.00 target price on shares of Tevogen Bio in a research report on Tuesday, March 11th.

Institutional Trading of Tevogen Bio

A number of institutional investors have recently made changes to their positions in TVGN. HGC Investment Management Inc. acquired a new stake in shares of Tevogen Bio in the 3rd quarter worth approximately $82,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Tevogen Bio in the 4th quarter worth approximately $38,000. JPMorgan Chase & Co. lifted its stake in shares of Tevogen Bio by 74.2% in the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock worth $40,000 after acquiring an additional 16,695 shares during the period. Geode Capital Management LLC lifted its stake in shares of Tevogen Bio by 31.2% in the 4th quarter. Geode Capital Management LLC now owns 451,851 shares of the company’s stock worth $465,000 after acquiring an additional 107,566 shares during the period. Finally, Barclays PLC lifted its stake in shares of Tevogen Bio by 39.2% in the 4th quarter. Barclays PLC now owns 45,600 shares of the company’s stock worth $48,000 after acquiring an additional 12,847 shares during the period.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.